BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
November 01, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month
October 12, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of...
BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments
October 11, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley
September 20, 2022 09:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and noninvasive treatment for...
BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™
September 14, 2022 07:30 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...
BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference
August 31, 2022 09:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Aug. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced and non-invasive treatment for...
BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression
August 29, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights
August 10, 2022 07:30 ET
|
BrainsWay
Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 10, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd....
BrainsWay to Report Second Quarter Financial Results on August 10, 2022
July 27, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression
June 28, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for...